G-CSF Monoclonal Antibody (9B4CSF), eFluor™ 660, eBioscience™, Invitrogen™

Description

Description: This 9B4CSF monoclonal antibody reacts with mouse G-CSF (Granulocyte Colony-Stimulating Factor), a growth factor that stimulates the proliferation, differentiation, and mobilization of hematopoetic stem cells. It is expressed by monocytes, macrophages, and bone marrow stromal cells, and can also be induced in fibroblasts by IL-17A. Unlike GM-CSF and IL-3, which can stimulate cells of multiple lineages, G-CSF activity is limited to neutrophilic granulocytes. G-CSF is essential to the maintece of neutrophil counts during homeostasis, and low basal levels of the protein are detectable in the serum of healthy individuals. Circulating levels become elevated rapidly upon infection, as G-CSF is also important for the activation and mobilization of mature neutrophils during the innate immune response. G-CSF therapy is commonly used to treat neutropenia following bone marrow transplant or chemotherapy. This 9B4CSF antibody has been demonstrated to cross-react with human G-CSF. Applications Reported: This 9B4CSF antibody has been reported for use in flow cytometric analysis, and intracellular staining followed by flow cytometric analysis. Applications Tested: This 9B2-8°CSF antibody has been tested by intracellular staining followed by flow cytometric analysis of in vitro-cultured and stimulated mouse monocytes/macrophages. This can be used at less than or equal to 0.06 μg per test.

G-CSF (Granulocyte colony stimulating factor) is a naturally occurring cytokine that stimulates the production and antibacterial function of neutrophils and monocytes. Human G-CSF is an 18.8 kDa protein containing 175 amino acid residues, and a soluble isoform of the G-CSF receptor has been described. The pleotropic cytokine is produced by activated monocytes, macrophages, endothelial cells, fibroblasts, astrocytes, osteoblasts and bone marrow cells. G-CSF has been shown to have specific effects on the proliferation, differentiation and activation of hematopoietic cells. G-CSF is also expressed by various transformed cells such as carcinoma cells and myeloblastic leukemia cells. G-CSF is encoded by two distinct DNA sequences, resulting in a full size, high activity and a shorter, low activity isoform of G-CSF. G-CSF is highly conserved among species and has been shown to exert its biological functions through interaction with its receptor expressed on the surface of hematopoietic progenitors, neutrophilic granulocytes and certain carcinoma cell lines. Clinical use of G-CSF has been approved for several therapeutic applications, treatment of neonatal infections, therapy of acute myocardial infarction, granulocyte transfusion in patients with neutropenia, in severe infections and sepsis, therapy in chronic autoimmune neutropenia, treatment of acute myeloid leukemias, Sweet's syndrome and AIDS. Further, G-CSF has been shown to be a marker protein for different carcinomas such as bladder cancer and dysfunction of the protein has been linked to Kostmann Syndrome.